MCID: CHR563
MIFTS: 48

Chronic Eosinophilic Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Chronic Eosinophilic Leukemia

MalaCards integrated aliases for Chronic Eosinophilic Leukemia:

Name: Chronic Eosinophilic Leukemia 12 58 36 15 71
Pdgfra-Associated Chronic Eosinophilic Leukemia 71

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0080367
KEGG 36 H01590
NCIt 49 C4563
ICD10 32 D47.5
ICD10 via Orphanet 33 D47.5
UMLS via Orphanet 72 C0346421
Orphanet 58 ORPHA168940
UMLS 71 C0346421 C3853548

Summaries for Chronic Eosinophilic Leukemia

KEGG : 36 Chronic eosinophilic leukemia (CEL) is a chronic myeloproliferative disease of unknown etiology in which a clonal proliferation of eosinophilic precursors results in a persistently elevated number of eosinophils in blood, bone marrow or peripheral tissues. In most patients with CEL (about 60%), eosinophils display PDGFRA-fusion genes and related cytogenetic defects. The most commonly detected oncoprotein is FIP1L1/PDGFRA. FIP1L1-PDGFRA is a constitutively activated tyrosine kinase, which is suggested to induce the proliferation of EoL-1 (The eosinophilic leukemia cell line) cells by inducing c-Myc expression at the mRNA level via ERK and JNK signaling pathways.

MalaCards based summary : Chronic Eosinophilic Leukemia, also known as pdgfra-associated chronic eosinophilic leukemia, is related to pdgfra-associated chronic eosinophilic leukemia and myeloproliferative neoplasm. An important gene associated with Chronic Eosinophilic Leukemia is FIP1L1 (Factor Interacting With PAPOLA And CPSF1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Prednisone and Antineoplastic Agents, Hormonal have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A chronic leukemia characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.

Wikipedia : 74 Chronic eosinophilic leukemia is a form of cancer in which too many eosinophils are found in the bone... more...

Related Diseases for Chronic Eosinophilic Leukemia

Diseases related to Chronic Eosinophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)
# Related Disease Score Top Affiliating Genes
1 pdgfra-associated chronic eosinophilic leukemia 35.3 PDGFRA FIP1L1
2 myeloproliferative neoplasm 31.0 WT1 U2AF1 PDGFRB PDGFRA KIT JAK2
3 hypereosinophilic syndrome, idiopathic 30.6 WT1 PDGFRB PDGFRA KIT IL5 FIP1L1
4 hypereosinophilic syndrome 30.4 PDGFRB PDGFRA KIT JAK2 IL5 IFNA1
5 budd-chiari syndrome 30.3 PDGFRA JAK2 FIP1L1
6 myeloid sarcoma 30.2 U2AF1 KIT FLT3
7 acute leukemia 30.2 WT1 KIT JAK2 FLT3 ETV6
8 endomyocardial fibrosis 30.2 PDGFRB PDGFRA IL5 FIP1L1 CHIC2
9 precursor t-cell acute lymphoblastic leukemia 30.0 FLT3 ETV6 ABL1
10 blood coagulation disease 30.0 U2AF1 KIT JAK2 IFNA1
11 loeffler endocarditis 30.0 PDGFRA IL5 FIP1L1 ETV6
12 thrombocytopenia 29.8 U2AF1 PDGFRA JAK2 IFNA1 ETV6
13 t-cell acute lymphoblastic leukemia 29.8 U2AF1 FLT3 ETV6 ABL1
14 mastocytosis 29.7 PDGFRB PDGFRA KIT JAK2 IFNA1 FLT3
15 leukemia 29.6 WT1 U2AF1 KIT JAK2 FLT3 FGFR1
16 juvenile myelomonocytic leukemia 29.5 U2AF1 PDGFRB PDGFRA JAK2 FLT3 ASXL1
17 leukemia, acute lymphoblastic 29.4 WT1 U2AF1 KIT JAK2 FLT3 ETV6
18 essential thrombocythemia 29.4 U2AF1 KIT JAK2 IFNA1 ASXL1 ABL1
19 sm-ahnmd 29.3 U2AF1 PDGFRA KIT JAK2 FIP1L1 CHIC2
20 systemic mastocytosis 29.2 U2AF1 PDGFRB PDGFRA KIT JAK2 IFNA1
21 myelofibrosis 29.0 WT1 U2AF1 PDGFRB KIT JAK2 IFNA1
22 myelodysplastic/myeloproliferative neoplasm 29.0 U2AF1 PDGFRB KIT JAK2 FLT3 ETV6
23 myeloid leukemia 28.9 WT1 U2AF1 KIT JAK2 FLT3 ETV6
24 atypical chronic myeloid leukemia 28.8 U2AF1 PDGFRB PDGFRA JAK2 FLT3 FGFR1
25 myelodysplastic syndrome 28.7 WT1 U2AF1 PDGFRB KIT JAK2 FLT3
26 polycythemia vera 28.3 U2AF1 PDGFRB PDGFRA KIT JAK2 IFNA1
27 leukemia, chronic myeloid 28.3 WT1 U2AF1 PDGFRB PDGFRA KIT JAK2
28 leukemia, acute myeloid 28.0 WT1 U2AF1 PDGFRB PDGFRA KIT JAK2
29 pdgfrb-associated chronic eosinophilic leukemia 12.8
30 reticular perineurioma 10.6 PDGFRA KIT
31 small intestinal sarcoma 10.5 PDGFRA KIT
32 deep leiomyoma 10.5 PDGFRA KIT
33 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.5 KIT FLT3
34 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.5 JAK2 ABL1
35 gastric leiomyoma 10.5 PDGFRA KIT
36 testicular gonadoblastoma 10.5 WT1 KIT
37 acute myeloblastic leukemia with maturation 10.5 KIT FLT3
38 pulmonary vein stenosis 10.5 PDGFRA KIT
39 laryngeal small cell carcinoma 10.5 PDGFRA KIT
40 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.5 PDGFRB PDGFRA FGFR1
41 gastric leiomyosarcoma 10.5 PDGFRA KIT
42 uterine sarcoma 10.5 WT1 KIT
43 cytogenetically normal acute myeloid leukemia 10.4 WT1 FLT3
44 small intestine leiomyoma 10.4 PDGFRA KIT
45 desmoid tumor 10.4 PDGFRB PDGFRA KIT
46 systemic mastocytosis with associated hematologic neoplasm 10.4 KIT ASXL1
47 lymphoblastic leukemia, acute, with lymphomatous features 10.4 JAK2 FGFR1 ABL1
48 colon leiomyosarcoma 10.4 WT1 PDGFRA KIT
49 brain stem glioma 10.4 PDGFRB PDGFRA FGFR1
50 mast-cell sarcoma 10.4 KIT FIP1L1

Graphical network of the top 20 diseases related to Chronic Eosinophilic Leukemia:



Diseases related to Chronic Eosinophilic Leukemia

Symptoms & Phenotypes for Chronic Eosinophilic Leukemia

GenomeRNAi Phenotypes related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.03 FLT3 PDGFRA
2 Decreased viability GR00221-A-1 10.03 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
3 Decreased viability GR00221-A-2 10.03 ABL1 FGFR1
4 Decreased viability GR00221-A-3 10.03 ABL1 PDGFRA PDGFRB
5 Decreased viability GR00221-A-4 10.03 FLT3 PDGFRA PDGFRB
6 Decreased viability GR00249-S 10.03 PDGFRA
7 Decreased viability GR00301-A 10.03 KIT
8 Decreased viability GR00342-S-1 10.03 ABL1 PDGFRB
9 Decreased viability GR00342-S-2 10.03 ABL1
10 Decreased viability GR00342-S-3 10.03 ABL1
11 Decreased viability GR00386-A-1 10.03 FGFR1
12 Decreased viability GR00402-S-2 10.03 PDGFRA
13 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT
14 Decreased substrate adherent cell growth GR00193-A-2 9.7 ABL1 KIT
15 Decreased substrate adherent cell growth GR00193-A-4 9.7 ABL1 FGFR1 FLT3 KIT
16 Resistant to vaccinia virus (VACV-A4L) infection GR00351-A-1 9.23 ABL1 FIP1L1 IFNA1 JAK2 OSM PDGFRA

MGI Mouse Phenotypes related to Chronic Eosinophilic Leukemia:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 ABL1 ASXL1 CDK5RAP2 ETV6 FGFR1 FLT3
2 hematopoietic system MP:0005397 10.33 ABL1 ASXL1 CDK5RAP2 CHIC2 ETV6 FGFR1
3 immune system MP:0005387 10.31 ABL1 ASXL1 CDK5RAP2 CHIC2 ETV6 FGFR1
4 growth/size/body region MP:0005378 10.29 ABL1 ASXL1 CDK5RAP2 ETV6 FGFR1 FLT3
5 endocrine/exocrine gland MP:0005379 10.24 ABL1 ASXL1 CHIC2 ETV6 FGFR1 FLT3
6 mortality/aging MP:0010768 10.21 ABL1 ASXL1 CDK5RAP2 CHIC2 ETV6 FGFR1
7 embryo MP:0005380 10.16 ABL1 ETV6 FGFR1 IL5 JAK2 KIT
8 digestive/alimentary MP:0005381 10.13 ABL1 ASXL1 ETV6 FGFR1 IL5 KIT
9 craniofacial MP:0005382 10.08 ABL1 ASXL1 CDK5RAP2 FGFR1 KIT PDGFRA
10 integument MP:0010771 10.06 CDK5RAP2 CHIC2 ETV6 FGFR1 JAK2 KIT
11 neoplasm MP:0002006 9.97 ASXL1 CDK5RAP2 ETV6 FLT3 IL5 JAK2
12 no phenotypic analysis MP:0003012 9.86 ETV6 FGFR1 FLT3 KIT PDGFRA SIGLEC8
13 reproductive system MP:0005389 9.81 CDK5RAP2 CHIC2 FGFR1 IL5 JAK2 KIT
14 respiratory system MP:0005388 9.5 ABL1 IL5 JAK2 KIT PDGFRA SIGLEC8
15 skeleton MP:0005390 9.28 ABL1 ASXL1 CDK5RAP2 FGFR1 FLT3 JAK2

Drugs & Therapeutics for Chronic Eosinophilic Leukemia

Drugs for Chronic Eosinophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2 Antineoplastic Agents, Hormonal Phase 4
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
5
Acyclovir Approved Phase 3 59277-89-3 2022
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
8
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
9
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
10
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
11
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
12
Polyestradiol phosphate Approved Phase 3 28014-46-2
13
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
14 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
15 Anesthetics, Dissociative Phase 3
16 Cola Phase 3
17 Liver Extracts Phase 3
18 Neurotransmitter Agents Phase 3
19 Analgesics, Opioid Phase 3
20 Antiprotozoal Agents Phase 3
21 Antiparasitic Agents Phase 3
22 Excitatory Amino Acid Antagonists Phase 3
23 Narcotics Phase 3
24 Analgesics Phase 3
25 valacyclovir Phase 3
26 Anesthetics Phase 3
27 Anesthetics, General Phase 3
28 Anesthetics, Intravenous Phase 3
29 Amebicides Phase 3
30 Liposomal amphotericin B Phase 3
31 Estradiol 17 beta-cypionate Phase 3
32 Contraceptives, Oral Phase 3
33 Contraceptive Agents Phase 3
34 Contraceptives, Oral, Combined Phase 3
35 Estradiol 3-benzoate Phase 3
36 Norgestimate, ethinyl estradiol drug combination Phase 3
37
alemtuzumab Approved, Investigational Phase 2 216503-57-0
38
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
39
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
40
Caspofungin Approved Phase 2 162808-62-0, 179463-17-3 2826718 468682
41
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
42
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
43
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Etoposide Approved Phase 2 33419-42-0 36462
46
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
47
Melphalan Approved Phase 2 148-82-3 460612 4053
48
rituximab Approved Phase 2 174722-31-7 10201696
49
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
50
Carmustine Approved, Investigational Phase 2 154-93-8 2578

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes Recruiting NCT01524536 Phase 4 prednisone
2 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
4 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
5 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
6 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
7 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
8 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
9 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
10 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
11 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
13 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
14 Open Label Pilot Phase II Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2 STI571
15 A Phase IA/II Multicenter, Dose-escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant/Intolerant CML in Chronic or Accelerated Phase or Blast Crisis, Relapsed/Refractory Ph+ ALL, and Other Hematologic Malignancies. Completed NCT00109707 Phase 1, Phase 2 Nilotinib
16 A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
17 Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
18 Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors Completed NCT00005622 Phase 2 cyclophosphamide
19 Conditioning With Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Allogeneic Marrow or Peripheral Blood Stem Cell (PBSC) Transplantation for Myelodysplasia and Myeloproliferative Disorders Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
20 Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
21 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
22 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
23 A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
24 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
25 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
26 A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
27 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
28 Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
29 HLA Matched Related and Unrelated Bone Marrow Transplantation With Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide for Hematological Malignancies Completed NCT00134017 Phase 2 Busulfan;Cyclophosphamide
30 Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
31 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
32 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
33 Randomized Trial of Unmanipulated Versus Expanded Cord Blood Completed NCT00067002 Phase 2 Rituxan;Melphalan;Thiotepa;Fludarabine;Cyclophosphamide;Mesna
34 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
35 A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
36 A Phase I/II Study of Double Unit Umbilical Cord Blood (UCB) Transplantation Utilizing Graft Administration Via Intra-Bone Marrow Injection (Companion Protocol to MT2000-25) Terminated NCT00295880 Phase 1, Phase 2
37 Conditioning for Graft Failure After Hematopoietic Stem Cell Transplantation Terminated NCT00617929 Phase 2 clofarabine
38 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
39 A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
40 Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
41 Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation Withdrawn NCT00301912 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
42 Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (CRBSI) Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
43 T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation Withdrawn NCT00816413 Phase 1, Phase 2 cyclosporine;mycophenolate mofetil;pentostatin
44 Emergency Access to C.V. pp65 / IE-1 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistant or Therapy Refractory Infections Unknown status NCT00769613 Phase 1
45 Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies Completed NCT00104923 Phase 1 fenretinide
46 A Dose Finding Study of R115777 (NSC 702818) in Patients With Advanced Hematologic Malignancies Completed NCT00005967 Phase 1 tipifarnib
47 A Phase I Study of 5-AZA-2'-Deoxycytidine and Depsipeptide in Patients With Relapsed/Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disease Completed NCT00114257 Phase 1 decitabine;romidepsin
48 Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies Completed NCT00073944 Phase 1 forodesine hydrochloride
49 Rasburicase to Prevent Graft -Versus-Host Disease Completed NCT00513474 Phase 1 busulfan;cyclophosphamide;cyclosporin-A;etoposide;methotrexate;rasburicase;sirolimus;tacrolimus;fludarabine;allopurinol
50 Donor Mesenchymal Stem Cell Infusion for Treatment of Graft Versus Host Disease: A Phase I Trial Completed NCT00361049 Phase 1

Search NIH Clinical Center for Chronic Eosinophilic Leukemia

Genetic Tests for Chronic Eosinophilic Leukemia

Anatomical Context for Chronic Eosinophilic Leukemia

MalaCards organs/tissues related to Chronic Eosinophilic Leukemia:

40
Bone, Bone Marrow, T Cells, Myeloid, Liver, Nk Cells, Testes

Publications for Chronic Eosinophilic Leukemia

Articles related to Chronic Eosinophilic Leukemia:

(show top 50) (show all 255)
# Title Authors PMID Year
1
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic. 61
32243620 2020
2
A Population-based Study of Chronic Eosinophilic Leukemia-Not Otherwise Specified in the United States. 61
32533865 2020
3
Feasibility of Combined Detection of Gene Mutations and Fusion Transcripts in Bone Marrow Trephines from Leukemic Neoplasms. 61
32036087 2020
4
The Efficacy of Imatinib Mesylate in the Treatment of a Rare Lytic Bone Lesion Caused by Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia: A Case Report. 61
32224679 2020
5
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. 61
31697804 2019
6
Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. 61
31421946 2019
7
World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. 61
31423623 2019
8
[Hypereosinophilic syndromes]. 61
32233322 2019
9
Causes of eosinophilic ascites - A systematic review. 61
30864403 2019
10
A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31). 61
30697976 2019
11
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. 61
30573779 2019
12
Clonal evolution revealed by next-generation sequencing in a long-term follow-up patient with hypereosinophilia. 61
31024795 2019
13
A multimodality work-up of patients with Hypereosinophilia. 61
30105844 2018
14
A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience. 61
30032299 2018
15
A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34). 61
29384404 2018
16
Cutaneous T-Cell Lymphoma, a Novel Manifestation of PDGFRA-Rearranged Neoplasm. 61
29505472 2018
17
[Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia]. 61
30032569 2018
18
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib. 61
28651427 2018
19
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. 61
29544149 2018
20
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. 61
29426921 2018
21
A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. 61
29892549 2018
22
[Chronic myeloid leukemia presenting with marked eosinophilia]. 61
30626795 2018
23
A Very Rare Case of Hypereosinophilic Syndrome Secondary to Natural Killer/T-Cell Lymphoma. 61
29785315 2018
24
Recurrent Malignancy-Associated Atypical Neutrophilic Dermatosis With Noninfectious Shock. 61
29208261 2017
25
World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. 61
29044676 2017
26
A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. 61
29025582 2017
27
Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL. 61
29029406 2017
28
Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report. 61
28885361 2017
29
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. 61
28495918 2017
30
Myeloid neoplasms with eosinophilia. 61
28028030 2017
31
Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation. 61
27267816 2017
32
Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities. 61
27960034 2017
33
Integration of a bacterial gene sequence into a chronic eosinophilic leukemia patient's genome as part of a fusion gene linker. 61
28593047 2017
34
When Hypereosinophilia Leads to Stroke. 61
30755950 2017
35
Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement. 61
27722133 2016
36
Early-Stage Loeffler's Endocarditis with Isolated Right Ventricular Involvement: Management, Long-Term Follow-Up, and Review of Literature. 61
27172873 2016
37
Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia. 61
27458550 2016
38
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. 61
27174585 2016
39
Chronic Eosinophilic Leukemia Presenting Predominantly with Cutaneous Manifestations. 61
27512192 2016
40
Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene. 61
26503642 2016
41
Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. 61
27120808 2016
42
Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis. 61
26404639 2015
43
World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. 61
26486351 2015
44
Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia. 61
26492057 2015
45
Hematologic Malignancies Identified in Patients with Hypereosinophilia and Hypereosinophilic Syndromes. 61
26342744 2015
46
Eosinophilia in Hematologic Disorders. 61
26209894 2015
47
A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome. 61
25962659 2015
48
F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance. 61
25761934 2015
49
Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia. 61
25923837 2015
50
Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene. 61
24975316 2015

Variations for Chronic Eosinophilic Leukemia

Expression for Chronic Eosinophilic Leukemia

Search GEO for disease gene expression data for Chronic Eosinophilic Leukemia.

Pathways for Chronic Eosinophilic Leukemia

Pathways related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 SIGLEC8 PDGFRB PDGFRA OSM KIT JAK2
2
Show member pathways
13.74 PDGFRB PDGFRA OSM KIT JAK2 IL5
3
Show member pathways
13.57 PDGFRB PDGFRA OSM KIT JAK2 IL5
4
Show member pathways
13.44 PDGFRB PDGFRA KIT JAK2 IL5 IFNA1
5
Show member pathways
13.3 PDGFRB PDGFRA OSM KIT JAK2 IL5
6
Show member pathways
13.26 PDGFRB PDGFRA OSM KIT JAK2 IL5
7
Show member pathways
13.2 PDGFRB PDGFRA OSM KIT JAK2 IL5
8
Show member pathways
12.85 PDGFRB PDGFRA KIT FLT3 FGFR1
9
Show member pathways
12.84 PDGFRB PDGFRA OSM KIT JAK2 IFNA1
10
Show member pathways
12.77 TPM3 PDGFRB PDGFRA KIT FLT3 FGFR1
11 12.66 PDGFRB PDGFRA KIT FLT3 FGFR1
12
Show member pathways
12.65 PDGFRB PDGFRA KIT FLT3 FGFR1 ABL1
13
Show member pathways
12.36 PDGFRB PDGFRA IL5 FGFR1
14
Show member pathways
12.29 PDGFRB PDGFRA KIT FLT3 FGFR1
15
Show member pathways
12.26 PDGFRB PDGFRA OSM JAK2 IL5 IFNA1
16 12.05 TPM3 PDGFRB PDGFRA KIT JAK2 IL5
17
Show member pathways
12.01 PDGFRB PDGFRA KIT IL5 IFNA1 FGFR1
18 11.9 SIGLEC8 KIT IL5 FLT3
19 11.81 KIT IL5 FLT3
20 11.75 PDGFRB PDGFRA FGFR1
21
Show member pathways
11.73 PDGFRB KIT FLT3 FGFR1
22 11.67 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
23
Show member pathways
11.45 PDGFRB PDGFRA KIT ABL1
24 11.4 PDGFRB PDGFRA FGFR1
25 11.4 PDGFRB PDGFRA KIT FLT3 FGFR1
26 11.37 PDGFRB PDGFRA FGFR1
27
Show member pathways
11.2 PDGFRB PDGFRA KIT FLT3
28 10.9 PDGFRB PDGFRA OSM KIT IL5 FLT3
29 10.78 PDGFRB PDGFRA

GO Terms for Chronic Eosinophilic Leukemia

Cellular components related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.02 PDGFRB PDGFRA KIT FLT3 FGFR1

Biological processes related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10.11 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
2 protein phosphorylation GO:0006468 10.09 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
3 positive regulation of cell proliferation GO:0008284 10.01 PDGFRB PDGFRA OSM KIT JAK2 IL5
4 cytokine-mediated signaling pathway GO:0019221 9.97 OSM KIT JAK2 IL5 IFNA1 FLT3
5 positive regulation of cell migration GO:0030335 9.96 PDGFRB PDGFRA KIT JAK2
6 positive regulation of protein kinase B signaling GO:0051897 9.92 PDGFRB PDGFRA OSM KIT FGFR1
7 positive regulation of MAPK cascade GO:0043410 9.89 OSM KIT FLT3 FGFR1
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 OSM JAK2 IL5 ABL1
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 PDGFRB PDGFRA KIT FLT3 FGFR1
10 MAPK cascade GO:0000165 9.87 PDGFRB PDGFRA KIT JAK2 IL5 FLT3
11 hematopoietic progenitor cell differentiation GO:0002244 9.86 PDGFRB PDGFRA KIT FLT3
12 male gonad development GO:0008584 9.85 WT1 PDGFRB KIT
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 OSM KIT JAK2 FLT3
14 cell chemotaxis GO:0060326 9.83 PDGFRB PDGFRA KIT
15 B cell differentiation GO:0030183 9.83 KIT IFNA1 FLT3
16 hemopoiesis GO:0030097 9.82 KIT FLT3 ASXL1
17 phosphatidylinositol-mediated signaling GO:0048015 9.81 PDGFRB PDGFRA FGFR1
18 positive regulation of MAP kinase activity GO:0043406 9.81 PDGFRB KIT FLT3 FGFR1
19 skeletal system morphogenesis GO:0048705 9.79 PDGFRB PDGFRA FGFR1
20 positive regulation of kinase activity GO:0033674 9.77 PDGFRB PDGFRA KIT FLT3 FGFR1
21 platelet-derived growth factor receptor signaling pathway GO:0048008 9.76 PDGFRB PDGFRA JAK2 ABL1
22 adrenal gland development GO:0030325 9.75 WT1 PDGFRB PDGFRA
23 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.73 PDGFRB PDGFRA KIT FLT3
24 protein autophosphorylation GO:0046777 9.7 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
25 cardiac myofibril assembly GO:0055003 9.67 PDGFRB PDGFRA
26 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.67 PDGFRB JAK2
27 negative regulation of cell-cell adhesion GO:0022408 9.66 JAK2 ABL1
28 metanephric mesenchyme development GO:0072075 9.64 WT1 PDGFRB
29 retina vasculature development in camera-type eye GO:0061298 9.64 PDGFRB PDGFRA
30 myeloid progenitor cell differentiation GO:0002318 9.63 KIT FLT3
31 metanephric S-shaped body morphogenesis GO:0072284 9.62 WT1 PDGFRB
32 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.62 PDGFRB ABL1
33 metanephric glomerular capillary formation GO:0072277 9.61 PDGFRB PDGFRA
34 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.6 PDGFRB PDGFRA
35 positive regulation of phospholipase C activity GO:0010863 9.56 PDGFRB PDGFRA KIT FGFR1
36 peptidyl-tyrosine phosphorylation GO:0018108 9.5 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
37 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.17 PDGFRB PDGFRA OSM KIT JAK2 FLT3

Molecular functions related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.41 WT1 U2AF1 TPM3 SIGLEC8 PDGFRB PDGFRA
2 kinase activity GO:0016301 9.91 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
3 protein kinase activity GO:0004672 9.87 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
4 growth factor binding GO:0019838 9.56 PDGFRB PDGFRA KIT FLT3
5 platelet-derived growth factor receptor binding GO:0005161 9.49 PDGFRB PDGFRA
6 platelet-derived growth factor binding GO:0048407 9.48 PDGFRB PDGFRA
7 SH2 domain binding GO:0042169 9.46 KIT JAK2 FGFR1 ABL1
8 vascular endothelial growth factor binding GO:0038085 9.43 PDGFRB PDGFRA
9 vascular endothelial growth factor-activated receptor activity GO:0005021 9.4 PDGFRA FLT3
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.35 PDGFRB PDGFRA KIT FLT3 FGFR1
11 protein tyrosine kinase activity GO:0004713 9.17 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1

Sources for Chronic Eosinophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....